Analysis of cytokine production by peanut-reactive T cells identifies residual Th2 effectors in highly allergic children who received peanut oral immunotherapy

Clinical and Experimental Allergy

Volumn 45, Issue 7, 2015, Pages 1201-1213

  Wisniewski, J A ^a   Commins, S P ^a   Agrawal, R ^a   Hulse, K E ^b   Yu, M D ^a   Cronin, J ^a   Heymann, P W ^a   Pomes, A ^c   Platts Mills, T A ^a   Workman, L ^a   Woodfolk, J A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c INDOOR Biotechnologies Inc   (United States)

Author keywords

Ara h 1; Ara h 2; Cytokines; IgE; Oral immunotherapy; Peanut allergy; Th1; Th2

Indexed keywords

ALLERGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; TRANSCRIPTION FACTOR FOXP3; ARA H 2 ALLERGEN, ARACHIS HYPOGAEA; GLYCOPROTEIN; IMMUNOGLOBULIN G; NAPIN; PLANT ANTIGEN;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EFFECTOR CELL; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; MALE; ORAL IMMUNOTHERAPY; PEANUT ALLERGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; STAINING; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; YOUNG ADULT; BIOSYNTHESIS; BLOOD; DESENSITIZATION; IMMUNOLOGY; IMMUNOPHENOTYPING; INFANT; METABOLISM; ORAL DRUG ADMINISTRATION; PEANUT HYPERSENSITIVITY; PRESCHOOL CHILD;

2S ALBUMINS, PLANT; ADMINISTRATION, ORAL; ADOLESCENT; ALLERGENS; ANTIGENS, PLANT; CHILD; CHILD, PRESCHOOL; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOPHENOTYPING; INFANT; INTERLEUKIN-4; MALE; PEANUT HYPERSENSITIVITY; T-LYMPHOCYTE SUBSETS; TH2 CELLS;

EID: 84930905394     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12537     Document Type: Article

References (42)

1. Fleischer DM, Perry TT, Atkins D et al. Allergic reactions to foods in preschool-aged children in a prospective observational food allergy study. Pediatrics 2012; 130:e25-32.
2. Sicherer SH. Epidemiology of food allergy. J Allergy Clin Immunol 2011; 127:594-602.
3. Vetander M, Helander D, Flodstrom C et al. Anaphylaxis and reactions to foods in children-a population-based case study of emergency department visits. Clin Exp Allergy 2012; 42:568-77.
4. Dang TD, Tang M, Choo S et al. Increasing the accuracy of peanut allergy diagnosis by using Ara h 2. J Allergy Clin Immunol 2012; 129:1056-63.
5. Nicolaou N, Poorafshar M, Murray C et al. Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. J Allergy Clin Immunol 2010; 125:191-7.
6. Turcanu V, Maleki SJ, Lack G. Characterization of lymphocyte responses to peanuts in normal children, peanut-allergic children, and allergic children who acquired tolerance to peanuts. J Clin Invest 2003; 111:1065-72.
7. DeLong JH, Simpson KH, Wambre E, James EA, Robinson D, Kwok WW. Ara h 1-reactive T cells in individuals with peanut allergy. J Allergy Clin Immunol 2011; 127:1211-8.
8. Shreffler WG, Castro RR, Kucuk ZY et al. The major glycoprotein allergen from Arachis hypogaea, Ara h 1, is a ligand of dendritic cell-specific ICAM-grabbing nonintegrin and acts as a Th2 adjuvant in vitro. J Immunol 2006; 177:3677-85.
9. Royer PJ, Emara M, Yang C et al. The mannose receptor mediates the uptake of diverse native allergens by dendritic cells and determines allergen-induced T cell polarization through modulation of IDO activity. J Immunol 2010; 185:1522-31.
10. Flinterman AE, Pasmans SG, den Hartog Jager CF et al. T cell responses to major peanut allergens in children with and without peanut allergy. Clin Exp Allergy 2010; 40:590-97.
11. Prussin C, Lee J, Foster B. Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5(-) T(H)2 responses. J Allergy Clin Immunol 2009; 124:1326-32.
12. Tordesillas L, Goswami R, Benede S et al. Skin exposure promotes a Th2-dependent sensitization to peanut allergens. J Clin Invest 2014; 124:4965-75.
13. Jones SM, Pons L, Roberts JL et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009; 124:292-300.
14. Patriarca G, Nucera E, Roncallo C et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther 2003; 17:459-65.
15. Nowak-Wegrzyn A, Albin S. Oral immunotherapy for food allergy: mechanisms and role in management. Clin Exp Allergy 2015; 45:368-83.
16. Syed A, Garcia MA, Lyu SC et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol 2014; 133:500-10.
17. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006; 25:195-201.
18. Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 2001; 107:891-6.
19. Hulse KE, Reefer AJ, Engelhard VH et al. Targeting allergen to FcgammaRI reveals a novel T(H)2 regulatory pathway linked to thymic stromal lymphopoietin receptor. J Allergy Clin Immunol 2010; 125:247-56.
20. Moller BK, Andresen BS, Christensen EI, Petersen CM. Surface membrane CD4 turnover in phorbol ester stimulated T-lymphocytes. Evidence of degradation and increased synthesis. FEBS Lett 1990; 276:59-62.
21. Mao JH, Chen ZM, Tang YM, Liang L, Du LZ, Zhang Y. Regulation of CD3, CD4 and CD8 expressions on PMA-activated human peripheral T cells. Zhejiang Da Xue Xue Bao Yi Xue Ban 2004; 33:155-9.
22. Baumgarth N, Roederer M. A practical approach to multicolor flow cytometry for immunophenotyping. J Immunol Methods 2000; 243:77-97.
23. Maecker HT, Trotter J. Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry A 2006; 69:1037-42.
24. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 2011; 79:167-74.
25. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114:371-6.
26. Gavin MA, Torgerson TR, Houston E et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006; 103:6659-64.
27. Allan SE, Crome SQ, Crellin NK et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19:345-54.
28. Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007; 123:18-29.
29. Reefer AJ, Carneiro RM, Custis NJ et al. A role for IL-10-mediated HLA-DR7-restricted T cell-dependent events in development of the modified Th2 response to cat allergen. J Immunol 2004; 172:2763-72.
30. Woodfolk JA. T-cell responses to allergens. J Allergy Clin Immunol 2007; 119:280-94.
31. Burastero SE. Pollen-cross allergenicity mediated by panallergens: a clue to the pathogenesis of multiple sensitizations. Inflamm Allergy Drug Targets 2006; 5:203-9.
32. Moran TP, Vickery BP, Burks AW. Oral and sublingual immunotherapy for food allergy: current progress and future directions. Curr Opin Immunol 2013; 25:781-7.
33. Wisniewski J, Agrawal R, Woodfolk JA. Mechanisms of tolerance induction in allergic disease: integrating current and emerging concepts. Clin Exp Allergy 2013; 43:164-6.
34. Wambre E, DeLong JH, James EA, LaFond RE, Robinson D, Kwok WW. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. J Allergy Clin Immunol 2012; 129:544-51.
35. Kim BS, Kim IK, Park YJ et al. Conversion of Th2 memory cells into Foxp3+ regulatory T cells suppressing Th2-mediated allergic asthma. Proc Natl Acad Sci USA 2010; 107:8742-47.
36. Anagnostou K, Islam S, King Y et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 2014; 383:1297-304.
37. Varshney P, Jones SM, Scurlock AM et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 2011; 127:654-60.
38. Nozawa A, Okamoto Y, Moverare R, Borres MP, Kurihara K. Monitoring Ara h 1, 2 and 3-sIgE and sIgG4 antibodies in peanut allergic children receiving oral rush immunotherapy. Pediatr Allergy Immunol 2014; 25:323-8.
39. Vickery BP, Lin J, Kulis M et al. Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. J Allergy Clin Immunol 2013; 131:128-34.
40. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004; 4:313-8.
41. Uermosi C, Beerli RR, Bauer M et al. Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol 2010; 126:375-83.
42. Burton OT, Logsdon SL, Zhou JS et al. Oral immunotherapy induces IgG antibodies that act through FcgammaRIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol 2014; 134:1310-17.